Skip to main content
Season 3 ends in 25 d 11:42:21 $2,000 10,000 pts = 1 month Premium
Health & Medicine

Lp(a) HORIZON: Pelacarsen Lowered Lp(a) but Not Heart Events

Published 12 min read
Open the post and read it to claim 30 points
Lipoprotein(a) particles flowing past a plaque inside a coronary artery, illustrating the Lp(a) HORIZON pelacarsen trial

Sign in and earn +30 points by reading this

Read to the end, wait a few seconds, then tap the claim button below.

In short

The Lp(a) HORIZON trial, published on 7 November 2026, found that pelacarsen cut lipoprotein(a) by about 78% but did not reduce heart attacks, strokes, urgent artery procedures or cardiovascular deaths [1][2]. Novartis has said it is ending the drug's heart-disease programme, while experts say measuring Lp(a) still matters [2][5].

Key takeaways

  1. In the NEJM paper, a primary event occurred in 12.3% of patients on pelacarsen and 12.1% on placebo (hazard ratio 1.02) over a median of 4.7 years [1][6].
  2. Lp(a) at 12 months was 64.4 nmol/L with pelacarsen versus 233.4 nmol/L with placebo [1].
  3. The trial enrolled 8,323 adults with established cardiovascular disease and Lp(a) of at least 70 mg/dL in 42 countries [2][4].
  4. Results were also neutral in patients with Lp(a) of 90 mg/dL or more and for death from any cause [1][2].
  5. Anaphylaxis occurred in 19 patients on pelacarsen and none on placebo, the AHA reports [2].
  6. Novartis said, as reported by TCTMD on 7 November 2026, that it has decided to discontinue the pelacarsen cardiovascular development programme [5].
  7. The result applies to pelacarsen only; other Lp(a) drugs are still in outcome trials [2][3].
On this page 13 sections
  1. What did the Lp(a) HORIZON trial find?
  2. What is lipoprotein(a) and why does it matter?
  3. How was the pelacarsen trial designed?
  4. How much did pelacarsen lower Lp(a)?
  5. Was pelacarsen safe in the trial?
  6. Why did lowering Lp(a) not prevent heart events?
  7. How do mg/dL and nmol/L Lp(a) results compare?
  8. What does Lp(a) HORIZON mean for other Lp(a) drugs?
  9. Should you still get an Lp(a) test?
  10. Common mistakes
  11. Frequently asked questions
  12. Glossary
  13. Sources

What did the Lp(a) HORIZON trial find?

Lp(a) HORIZON found that pelacarsen did not lower the risk of major adverse cardiovascular events compared with placebo, even though it strongly reduced Lp(a) [1]. The results were presented on 7 November 2026 at the American Heart Association's Scientific Sessions in Chicago and published the same day in The New England Journal of Medicine, with extended analyses in NEJM Evidence [1][2].

The primary end point was a composite of death from cardiovascular causes, nonfatal heart attack, nonfatal stroke or urgent coronary revascularization (an emergency procedure to reopen heart arteries) [1]. Over a median follow-up of 4.7 years, an event occurred in 511 patients (12.3%) given pelacarsen and 503 (12.1%) given placebo, a hazard ratio of 1.02 (95% confidence interval 0.90 to 1.15; P = 0.76) [1][6]. A hazard ratio of about 1 means no difference in risk.

"I cannot avoid the disappointing conclusion – it didn't work," said senior author Steven Nissen of the Cleveland Clinic, calling the neutral finding "unexpected and surprising to the medical community" [2].

What is lipoprotein(a) and why does it matter?

Lipoprotein(a), or Lp(a), is a form of cholesterol-carrying particle that shares features with LDL ("bad") cholesterol, including helping plaque build up in arteries [2]. The AHA says Lp(a) levels are largely genetically determined and stay fairly stable over a lifetime [2].

  • High Lp(a), 125 nmol/L or more (55 mg/dL or more), is associated with about a 1.4-fold higher long-term risk of heart attack or stroke [2].
  • A level of 250 nmol/L (115 mg/dL) is associated with at least double the long-term risk [2].
  • About 1 in 5 people worldwide, roughly 1.4 billion, are thought to have elevated Lp(a) [2]. Novartis gives the same one-in-five estimate [4].

Diet, exercise and statins have little effect on Lp(a), and there is currently no FDA-approved medicine to lower it, according to the AHA [2]. That is why a drug that lowers Lp(a) and prevents heart events was so eagerly awaited.

A lipoprotein(a) blood test tube in front of a lab lipid analyser, showing how Lp(a) is measured
Lp(a) is measured with a blood test and is largely inherited.

How was the pelacarsen trial designed?

Lp(a) HORIZON was a double-blind, randomised, placebo-controlled phase 3 trial at 797 sites in 42 countries, run from 2019 to 2026 [2].

  • Who: 14,249 adults were screened and 8,323 enrolled, with a mean age of 60, 27% women and 26% with diabetes; all had established cardiovascular disease [2]. The NEJM paper reports 8,350 randomised and 8,322 in the efficacy analysis [1][6].
  • Lp(a) level: all had at least 70 mg/dL (about 148 nmol/L); the median at the start was 236 nmol/L [1][2].
  • Background care: nearly all took antiplatelet medicines and 77-78% took high-intensity statins [2].
  • Treatment: pelacarsen or placebo as a monthly injection under the skin [1][2].

Pelacarsen is an antisense oligonucleotide, a short piece of synthetic genetic material that enters liver cells and blocks the production of Lp(a) [1][2]. The trial was funded by Novartis [1][2].

An illustrative injection pen beside a plain white medicine carton and a closed binder, representing the pelacarsen trial
Pelacarsen or placebo was given as a monthly injection under the skin.

How much did pelacarsen lower Lp(a)?

At 12 months, Lp(a) was 64.4 nmol/L in the pelacarsen group and 233.4 nmol/L in the placebo group [1]. The AHA and ACC describe the 12-month effect as about a 78% reduction from baseline (the ACC gives 78.4%), and the ACC adds that the time-averaged change over about five years was -73.9% [2][3]. The 78% is a percentage-change figure and is not simply the gap between the two medians above [6].

The lack of benefit held in the subgroup with the highest levels. Among patients with Lp(a) of at least 90 mg/dL, about the highest 15% of people worldwide, events occurred in 402 of 3,266 (12.3%) on pelacarsen and 403 of 3,274 (12.3%) on placebo, a hazard ratio of 1.00 [1][2].

Extended analyses of secondary outcomes, including death from any cause, were "consistent and unchanged" between groups, the AHA says [2]. "There was basically no effect on outcomes, not even a trend, even in subpopulations," Nissen said [2].

Was pelacarsen safe in the trial?

Serious adverse events were similar or slightly lower with pelacarsen (37.3%) than with placebo (41.1%), but some reactions were more common with the drug [1][2].

  • Flu-like symptoms, injection-site reactions and acute allergic reactions were more frequent with pelacarsen [2].
  • Anaphylaxis, a severe allergic reaction, occurred in 19 patients on pelacarsen and none on placebo; there were no deaths from these reactions [2].
  • About 21% of patients on pelacarsen and just over 7% on placebo stopped the study medicine because of adverse reactions [2].

The ACC summary also notes "treatment-limiting adverse events and rare hypersensitivity reactions" with pelacarsen [3]. These figures come from a trial population with existing heart disease and should not be applied to other Lp(a) drugs [3].

Why did lowering Lp(a) not prevent heart events?

The researchers say they do not yet know, and that more research is needed into how Lp(a) causes harm and how it interacts with other risk factors [2]. "This does not mean Lp(a) is irrelevant," Nissen said. "It means we need more in-depth research to help us fully understand the underlying mechanisms of Lp(a)" [2].

Some features of the trial are relevant when reading the result. Patients were already well treated: about 75% met guideline targets for blood pressure and cholesterol at entry, nearly all took antiplatelet medicines and most took high-intensity statins [2]. Novartis framed the trial as testing whether lowering Lp(a) reduces "residual cardiovascular risk beyond optimized, guideline-directed care" [4]. The trial did not test people without prior cardiovascular disease [3].

The ACC summary notes that siRNA drugs, a different class, may lower Lp(a) further and be better tolerated, but that is a hypothesis to be tested in their own trials, not a finding of this one [3]. Any explanation offered online before those trials report should be treated as speculation.

How do mg/dL and nmol/L Lp(a) results compare?

Lp(a) results are reported either in milligrams per decilitre (mg/dL) or nanomoles per litre (nmol/L), and the AHA gives approximate equivalents [2].

  • 70 mg/dL is about 148 nmol/L, the trial's entry threshold [2].
  • 90 mg/dL is about 192 nmol/L, the trial's high subgroup [2].
  • 125 nmol/L or more (55 mg/dL or more) is the AHA's marker of high Lp(a) [2].

When comparing a lab report with news coverage, check which unit is used before drawing any conclusion, and ask the lab or a doctor if unsure.

What does Lp(a) HORIZON mean for other Lp(a) drugs?

It is a setback, but researchers stress it does not settle whether lowering Lp(a) can work [2][3]. "A single trial does not provide definitive evidence of a lack of benefit of lowering Lp(a) as a strategy to reduce the cardiovascular risk," Nissen told the ACC [3].

The ACC summary lists limitations: the trial included only people who had already had cardiovascular events, so prevention in people without heart disease was not tested; and the result applies only to pelacarsen, while siRNA drugs may lower Lp(a) further and be better tolerated [3]. The AHA adds that some events occurred during COVID-19 and could not be separated out, and that 78% of participants were white and fewer than 4% of African ancestry, a group with Lp(a) levels about twice as high on average [2].

Nissen said three other outcome trials are under way for investigational compounds that target Lp(a) in different ways [2]. He urged people already in Lp(a) trials not to drop out because of these findings [2].

Novartis announced topline results on 4 September 2026 [4]. On 7 November 2026 TCTMD reported a Novartis statement that the company has decided to discontinue the pelacarsen cardiovascular development programme, including ongoing cardiovascular studies and its managed access programme [5].

A 3D human heart with gold-lit coronary arteries, illustrating cardiovascular outcomes in Lp(a) research
Pelacarsen did not change heart attack, stroke or cardiovascular death rates.

Should you still get an Lp(a) test?

Yes, according to the trial's own researchers and the AHA: Lp(a) remains a risk factor worth knowing, and the guideline recommends measuring it at least once in adulthood [2]. "Measuring Lp(a) is still absolutely worthwhile," Nissen said, noting that high levels usually cause no symptoms [2].

A result is used alongside blood pressure, cholesterol and blood sugar to estimate overall cardiovascular risk and guide prevention [2]. If you have questions about your number, the right person to ask is a doctor who can see your full risk profile. Health chatbots can misread lab values, as AI Hallucinations Explained: Why Chatbots Make Things Up and How to Get Accurate Answers and AI in Healthcare: What It Can Do Today, Where It Fails and How It Is Regulated explain.

This is not medical advice. Do not start, stop or change any medicine because of this trial without talking to your doctor.

Lp(a) HORIZON main results (NEJM, 7 November 2026)
MeasurePelacarsenPlacebo
Patients in efficacy analysis4,1574,165
Lp(a) at 12 months (nmol/L)64.4233.4
Primary events, all patients511 (12.3%)503 (12.1%)
Primary events, Lp(a) 90 mg/dL or more402 of 3,266 (12.3%)403 of 3,274 (12.3%)
Serious adverse events37.3%41.1%

Common mistakes

  • Saying Lp(a) does not matter after this trial.

    Fix: The researchers say Lp(a) remains an important risk factor; only this drug failed to change outcomes [2].

  • Assuming all Lp(a)-lowering drugs have failed.

    Fix: The result applies to pelacarsen; other drugs using different approaches are still in outcome trials [2][3].

  • Treating a lower lab number as proof of benefit.

    Fix: Pelacarsen cut Lp(a) by about 78% without reducing heart events [2][3].

  • Quoting the event counts the wrong way round.

    Fix: The NEJM paper reports 511 events on pelacarsen and 503 on placebo; the ACC summary lists the two numbers the other way round [1][3][6].

Frequently asked questions

What did the Lp(a) HORIZON trial find?

Pelacarsen did not reduce major cardiovascular events versus placebo: 12.3% vs 12.1%, hazard ratio 1.02 [1].

What is lipoprotein(a) and why does it matter?

A largely inherited cholesterol-carrying particle linked to plaque and higher heart attack and stroke risk [2].

How was the pelacarsen trial designed?

A phase 3 placebo-controlled trial of 8,323 adults with heart disease and high Lp(a) in 42 countries [2].

How much did pelacarsen lower Lp(a)?

About 78% from baseline at 12 months according to the AHA and ACC; the 12-month medians were 64.4 vs 233.4 nmol/L [1][2][3].

Was pelacarsen safe in the trial?

Serious events were similar, but allergic reactions, including 19 cases of anaphylaxis, were more common with the drug [2].

Why did lowering Lp(a) not prevent heart events?

The researchers say the reason is not yet known and more research on Lp(a) mechanisms is needed [2].

How do mg/dL and nmol/L Lp(a) results compare?

Approximately, 70 mg/dL is 148 nmol/L and 90 mg/dL is 192 nmol/L, per the AHA [2].

What does Lp(a) HORIZON mean for other Lp(a) drugs?

Researchers say it applies to pelacarsen only; other outcome trials continue [2][3].

Should you still get an Lp(a) test?

The AHA says yes: the guideline recommends measuring Lp(a) at least once in adulthood [2].

Glossary

Lp(a)
Lipoprotein(a), a largely inherited cholesterol-carrying particle linked to cardiovascular risk [2].
MACE
Major adverse cardiovascular events; here cardiovascular death, nonfatal heart attack, nonfatal stroke or urgent revascularization [1].
Hazard ratio
A comparison of event risk over time between groups; 1.0 means no difference [1].
Antisense oligonucleotide
A short synthetic strand of genetic material that blocks production of a protein; pelacarsen is one [1][2].
Secondary prevention
Treatment for people who already have cardiovascular disease, as in this trial [3].

Sources

  1. Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a) (N Engl J Med, doi:10.1056/NEJMoa2610159) New England Journal of Medicine via PubMed · 2026-11-07
  2. Lp(a) HORIZON trial: Lp(a) fell by 78%, but cardiovascular outcomes unexpectedly neutral American Heart Association · 2026-11-07
  3. Lp(a) HORIZON: Pelacarsen vs. Placebo in Patients With High Lp(a) American College of Cardiology · 2026-11-07
  4. Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen Novartis · 2026-09-04
  5. Full Lp(a)HORIZON Results Affirm Lack of Pelacarsen Benefit in Secondary Prevention TCTMD · 2026-11-07
  6. Lp(a)HORIZON shows pelacarsen lowers Lp(a) 78% but not cardiovascular events HCPLive · 2026-11-07
Share this guide Telegram WhatsApp X
0 likes

Comments

Top comments

About the Pouyam Team Editorial policy

On Pouyam

Explore Pouyam

Guides are one corner of Pouyam. Here is where to go next.

Quick navigation